Welcome & Explanation of Patient Input Submissions

The Canadian Agency for Drugs and Technologies in Health (CADTH) is interested in understanding the real impact that diseases and their treatments have on the daily lives of patients and caregivers. This helps inform their decisions of drug approvals and funding.
 
Asthma Canada helps patients have a say in the consideration of medications related to asthma and comorbidities including nasal polyps.
 
The following survey has been created to determine how nasal polyps affects your day-to-day life. This helps decision makers understand the personal implications of a particular illness and its treatments. Information received will be submitted to CADTH to inform their consideration of a new treatment option to Canada:
 
- Nucala (mepolizumab) is a prescription medicine for add-on maintenance treatment of severe chronic rhinosinusitis with nasal polyps (CRSwNP) in adults whose disease is inadequately controlled by intranasal corticosteroids alone.
 
This is an important way for your voice to be heard by the Government of Canada to help influence key decisions that will affect the asthma community.
 
In order to add your voice to this process, please complete this survey by Tuesday May 24, 2022. It should take about ten minutes of your time. Thank you!

T